A process for preparing pharmaceutically active compounds of formula (I) or a salt thereof
wherein R
1
, n, m, R
3
, R
6
, X
1
, X
2
, X
3
and X
4
are as defined in the specification, is described. Novel intermediates are also described and claimed.
A process for preparing pharmaceutically active compounds of formula (I) or a salt thereof
wherein R1, n, m, R3, R6, X1, X2, X3 and X4 are as defined in the specification, is described. Novel intermediates are also described and claimed.
Crystalline polymorphic form of glucokinase activator
申请人:AstraZeneca AB
公开号:US08093252B2
公开(公告)日:2012-01-10
A new polymorphic form of 3-[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide, processes for making it and its use as an activator of glucokinase are described.